{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:57:17Z","timestamp":1788184637176,"version":"build-2803163510"},"reference-count":116,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clml.2025.06.017","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T10:19:06Z","timestamp":1750587546000},"page":"8-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["SOHO State of the Art Updates and Next Questions | The Optimal Management of Waldenstr\u00f6m Macroglobulinemia"],"prefix":"10.1016","volume":"26","author":[{"given":"Alberto","family":"Guijosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia de las","family":"Heras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayna","family":"Sarosiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.06.017_bib0001","first-page":"217","article-title":"Incipient myelomatosis or \u2018essential\u2019 hyperglobulinemia with fibrinogenopenia a new syndrome?","volume":"CXVII","author":"Waldenstr\u00f6m","year":"1944","journal-title":"Acta Medica Scandinavica"},{"issue":"7","key":"10.1016\/j.clml.2025.06.017_bib0002","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2025.06.017_bib0003","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2025.06.017_bib0004","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2025.06.017_bib0005","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjh.15560","article-title":"TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstrom macroglobulinaemia","volume":"184","author":"Gustine","year":"2019","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.clml.2025.06.017_bib0006","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.06.017_bib0007","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/sonc.2003.50038","article-title":"Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's macroglobulinemia","volume":"30","author":"Kyle","year":"2003","journal-title":"Semin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.06.017_bib0008","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3109\/10428194.2012.656103","article-title":"Waldenstrom macroglobulinemia: a Surveillance, Epidemiology, and End results database review from 1988 to 2005","volume":"53","author":"Sekhar","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"10.1016\/j.clml.2025.06.017_bib0009","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1182\/blood-2014-05-574871","article-title":"Survival trends in Waldenstrom macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database","volume":"123","author":"Castillo","year":"2014","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2025.06.017_bib0010","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1158\/1078-0432.CCR-07-0299","article-title":"Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families","volume":"13","author":"McMaster","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.clml.2025.06.017_bib0011","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/annonc\/mdj111","article-title":"Characterization of familial Waldenstrom's macroglobulinemia","volume":"17","author":"Treon","year":"2006","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.06.017_bib0012","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.06.017_bib0013","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","article-title":"A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.06.017_bib0014","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.16088","article-title":"CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstrom macroglobulinaemia treated with ibrutinib","volume":"187","author":"Castillo","year":"2019","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1016\/j.clml.2025.06.017_bib0015","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1182\/blood-2014-03-564583","article-title":"C1013G\/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma","volume":"123","author":"Roccaro","year":"2014","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2025.06.017_bib0016","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1158\/1078-0432.CCR-17-0007","article-title":"TP53 Mutation and its prognostic significance in Waldenstrom's macroglobulinemia","volume":"23","author":"Poulain","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.clml.2025.06.017_bib0017","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/bjh.15049","article-title":"MYD88 wild-type Waldenstrom macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival","volume":"180","author":"Treon","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2025.06.017_bib0018","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ajh.25697","article-title":"Impact of MYD88(L265P) mutation status on histological transformation of Waldenstrom Macroglobulinemia","volume":"95","author":"Zanwar","year":"2020","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.clml.2025.06.017_bib0019","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/leu.2014.65","article-title":"Detection of MYD88 L265P in peripheral blood of patients with Waldenstrom's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance","volume":"28","author":"Xu","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2025.06.017_bib0020","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/PAS.0000000000000411","article-title":"MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma","volume":"39","author":"Martinez-Lopez","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"7354","key":"10.1016\/j.clml.2025.06.017_bib0021","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.clml.2025.06.017_bib0022","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/ajh.24753","article-title":"IgM myeloma: a multicenter retrospective study of 134 patients","volume":"92","author":"Castillo","year":"2017","journal-title":"Am J Hematol"},{"issue":"20","key":"10.1016\/j.clml.2025.06.017_bib0023","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1182\/blood.2021011452","article-title":"IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM","volume":"138","author":"Bazarbachi","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.06.017_bib0024","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.14196","article-title":"Recommendations for the diagnosis and initial evaluation of patients with Waldenstrom macroglobulinaemia: a Task Force from the 8th International Workshop on Waldenstrom Macroglobulinaemia","volume":"175","author":"Castillo","year":"2016","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.clml.2025.06.017_bib0026","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1182\/blood-2011-10-384768","article-title":"Progression in smoldering Waldenstrom macroglobulinemia: long-term results","volume":"119","author":"Kyle","year":"2012","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2025.06.017_bib0027","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.19.00394","article-title":"Progression risk stratification of asymptomatic Waldenstrom Macroglobulinemia","volume":"37","author":"Bustoros","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.06.017_bib0028","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/bjh.15201","article-title":"Prevalence and survival of smouldering Waldenstrom macroglobulinaemia in the United States","volume":"184","author":"Pophali","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.06.017_bib0029","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/sonc.2003.50051","article-title":"Asymptomatic Waldenstrom's macroglobulinemia","volume":"30","author":"Alexanian","year":"2003","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.06.017_bib0030","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.17691","article-title":"Disease outcomes and biomarkers of progression in smouldering Waldenstrom macroglobulinaemia","volume":"195","author":"Zanwar","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.06.017_bib0031","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clml.2013.02.005","article-title":"Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenstrom macroglobulinemia","volume":"13","author":"Kyle","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.clml.2025.06.017_bib0032","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1158\/1078-0432.CCR-04-1899","article-title":"Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?","volume":"11","author":"Gobbi","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.clml.2025.06.017_bib0033","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjh.14279","article-title":"Renal disease related to Waldenstrom macroglobulinaemia: incidence, pathology and clinical outcomes","volume":"175","author":"Vos","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2025.06.017_bib0034","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/bjh.13883","article-title":"Central nervous system involvement by Waldenstrom macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study","volume":"172","author":"Castillo","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.017_bib0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1529-8027.2012.00376.x","article-title":"Heterogeneous spectrum of neuropathies in Waldenstrom's macroglobulinemia: a diagnostic strategy to optimize their management","volume":"17","author":"Viala","year":"2012","journal-title":"J Peripher Nerv Syst"},{"issue":"13","key":"10.1016\/j.clml.2025.06.017_bib0036","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood-2018-06-846816","article-title":"Acute hyperviscosity: syndromes and management","volume":"132","author":"Gertz","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.06.017_bib0037","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bjh.14743","article-title":"Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenstrom macroglobulinaemia","volume":"177","author":"Gustine","year":"2017","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.clml.2025.06.017_bib0038","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/ajh.25254","article-title":"Predictors of symptomatic hyperviscosity in Waldenstrom macroglobulinemia","volume":"93","author":"Abeykoon","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.06.017_bib0039","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/asheducation-2004.1.257","article-title":"Amyloidosis and Waldenstrom's macroglobulinemia","author":"Gertz","year":"2004","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.clml.2025.06.017_bib0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjh.19112","article-title":"Clinical and clonal characteristics of monoclonal immunoglobulin M-associated type I cryoglobulinaemia","volume":"204","author":"Khwaja","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.06.017_bib0041","doi-asserted-by":"crossref","DOI":"10.1080\/14737140.2025.2488312","article-title":"Current and emerging treatment perspectives for adults with waldenstrom macroglobulinemia","author":"Guijosa","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"issue":"21","key":"10.1016\/j.clml.2025.06.017_bib0042","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.23.02066","article-title":"Simplified risk stratification model for patients with Waldenstrom macroglobulinemia","volume":"42","author":"Zanwar","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.06.017_bib0043","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.12102","article-title":"Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop","volume":"160","author":"Owen","year":"2013","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.06.017_bib0044","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.seminhematol.2023.03.009","article-title":"Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria","volume":"60","author":"Treon","year":"2023","journal-title":"Semin Hematol"},{"issue":"5","key":"10.1016\/j.clml.2025.06.017_bib0045","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2141.2009.07892.x","article-title":"Clinical value of minor responses after 4 doses of rituximab in Waldenstrom macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial","volume":"147","author":"Gertz","year":"2009","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.06.017_bib0046","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2141.2011.08726.x","article-title":"Attainment of complete\/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia","volume":"154","author":"Treon","year":"2011","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2025.06.017_bib0047","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bjh.17225","article-title":"Partial response or better at six months is prognostic of superior progression-free survival in Waldenstrom macroglobulinaemia patients treated with ibrutinib","volume":"192","author":"Castillo","year":"2021","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2025.06.017_bib0048","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/ajh.27663","article-title":"Depth of response from fixed-duration treatment is associated with superior survival in Waldenstrom Macroglobulinemia","volume":"100","author":"Paludo","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.06.017_bib0049","unstructured":"National Comprehensive Cancer N. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma. 2025. www.nccn.org\/professional\/physician_gls\/pdf\/waldenstroms.pdf. Accessed June 1, 2025."},{"issue":"9873","key":"10.1016\/j.clml.2025.06.017_bib0056","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.clml.2025.06.017_bib0058","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","article-title":"Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study","volume":"126","author":"Kastritis","year":"2015","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2025.06.017_bib0077","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2019-121909","volume":"134","author":"Rummel","year":"2019","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2025.06.017_bib0069","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","article-title":"Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180","volume":"27","author":"Treon","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.06.017_bib0067","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2016-09-742411","article-title":"Bortezomib, Dexamethasone and Rituximab in newly diagnosed patients with Waldenstr\u00f6M\u2019s macroglobulinemia: final analysis of a phase 2 study after a minimum follow up of 6 years","volume":"129","author":"Gavriatopoulou","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.06.017_bib0070","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","article-title":"Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia","volume":"124","author":"Treon","year":"2014","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2025.06.017_bib0071","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1182\/bloodadvances.2020001963","article-title":"Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstrom macroglobulinemia: long-term follow-up","volume":"4","author":"Castillo","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2025.06.017_bib0101","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.21.00105","article-title":"Combining Ixazomib with subcutaneous Rituximab and Dexamethasone in relapsed or refractory Waldenstrom's macroglobulinemia: final analysis of the phase I\/II HOVON124\/ECWM-R2 study","volume":"40","author":"Kersten","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.06.017_bib0080","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.20.00555","article-title":"Long-term follow-up of Ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstrom macroglobulinemia","volume":"39","author":"Treon","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.06.017_bib0082","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41375-021-01417-9","article-title":"Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia","volume":"36","author":"Castillo","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2025.06.017_bib0102","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.017_bib0087","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib plus Rituximab versus Placebo plus Rituximab for Waldenstrom's macroglobulinemia: final analysis from the randomized phase III iNNOVATE study","volume":"40","author":"Buske","year":"2022","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.clml.2025.06.017_bib0091","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib versus Ibrutinib in symptomatic Waldenstrom Macroglobulinemia: final analysis from the randomized phase III ASPEN study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.017_bib0104","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.21.01194","article-title":"Venetoclax in previously treated Waldenstrom Macroglobulinemia","volume":"40","author":"Castillo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.06.017_bib0106","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/blood-2022-159123","article-title":"Efficacy of Pirtobrutinib, a highly selective, non-covalent (Reversible) BTK inhibitor in relapsed \/refractory Waldenstr\u00f6m macroglobulinemia: results from the phase 1\/2 BRUIN study","volume":"140","author":"Palomba","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.017_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102510","article-title":"Management of indolent B-cell lymphomas: a review of approved and emerging targeted therapies","volume":"113","author":"Smyth","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.clml.2025.06.017_bib0051","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009212","article-title":"Bendamustine-rituximab elicits dual tumoricidal and immunomodulatory responses via cGAS-STING activation in diffuse large B-cell lymphoma","volume":"12","author":"Xiao","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clml.2025.06.017_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102715","article-title":"How to manage waldenstrom's macroglobulinemia in 2024","volume":"125","author":"Grunenberg","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"16","key":"10.1016\/j.clml.2025.06.017_bib0053","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1182\/blood-2008-09-177329","article-title":"Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia","volume":"113","author":"Treon","year":"2009","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2025.06.017_bib0054","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.2009.23.6315","article-title":"Rituximab and subcutaneous 2-chloro-2\u2032-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study","volume":"28","author":"Laszlo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.06.017_bib0055","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1200\/JCO.2007.15.1530","article-title":"Increased incidence of transformation and myelodysplasia\/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs","volume":"27","author":"Leleu","year":"2009","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.clml.2025.06.017_bib0057","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","article-title":"Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide","volume":"25","author":"Dimopoulos","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.017_bib0059","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.15148","article-title":"Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstrom macroglobulinaemia","volume":"181","author":"Castillo","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.017_bib0060","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ajh.27524","article-title":"First-line treatment of Waldenstrom's macroglobulinemia in Italy: a multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies","volume":"100","author":"Autore","year":"2025","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.clml.2025.06.017_bib0061","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00277-018-3311-z","article-title":"Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia","volume":"97","author":"Paludo","year":"2018","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.clml.2025.06.017_bib0062","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.3109\/10428194.2015.1012714","article-title":"Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstrom macroglobulinemia","volume":"56","author":"Tedeschi","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.clml.2025.06.017_bib0063","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1111\/bjh.19409","article-title":"Long-term results of Waldenstrom macroglobulinaemia treatment by bendamustine and rituximab: a study on behalf of the French Innovative Leukemia Organization (FILO)","volume":"204","author":"Laribi","year":"2024","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.clml.2025.06.017_bib0064","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/bloodadvances.2021004926","article-title":"Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenstrom macroglobulinemia","volume":"6","author":"Tahri","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2025.06.017_bib0065","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/hon.3128","article-title":"Risk of a second cancer and infection in patients with indolent B-cell lymphoma exposed to first-line bendamustine plus rituximab: a retrospective analysis of an administrative claims database","volume":"41","author":"Dote","year":"2023","journal-title":"Hematol Oncol"},{"issue":"19","key":"10.1016\/j.clml.2025.06.017_bib0066","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","article-title":"Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)","volume":"122","author":"Dimopoulos","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.06.017_bib0068","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ajh.21788","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia","volume":"85","author":"Ghobrial","year":"2010","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.clml.2025.06.017_bib0072","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1158\/1078-0432.CCR-18-0152","article-title":"Prospective clinical trial of Ixazomib, Dexamethasone, and Rituximab as primary therapy in Waldenstrom Macroglobulinemia","volume":"24","author":"Castillo","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.clml.2025.06.017_bib0073","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.22.01805","article-title":"Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenstr\u00f6m Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"41","author":"Buske","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.06.017_bib0074","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/cncr.20658","article-title":"Initial immunoglobulin M \u2018flare\u2019 after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia","volume":"101","author":"Ghobrial","year":"2004","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.clml.2025.06.017_bib0075","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/annonc\/mdh403","article-title":"Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia","volume":"15","author":"Treon","year":"2004","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.06.017_bib0076","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bjh.14743","article-title":"Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenstr\u00f6m macroglobulinaemia","volume":"177","author":"Gustine","year":"2017","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1016\/j.clml.2025.06.017_bib0078","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1182\/blood.2022017235","article-title":"How I use genomics and BTK inhibitors in the treatment of Waldenstrom macroglobulinemia","volume":"143","author":"Treon","year":"2024","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2025.06.017_bib0079","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2025.06.017_bib0081","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1182\/bloodadvances.2021006106","article-title":"Response and survival predictors in a cohort of 319 patients with Waldenstrom macroglobulinemia treated with ibrutinib monotherapy","volume":"6","author":"Castillo","year":"2022","journal-title":"Blood Adv"},{"issue":"27","key":"10.1016\/j.clml.2025.06.017_bib0083","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenstrom Macroglobulinemia","volume":"36","author":"Treon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.clml.2025.06.017_bib0084","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of Ibrutinib plus Rituximab in Waldenstrom's macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.clml.2025.06.017_bib0085","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1158\/1078-0432.CCR-21-1497","article-title":"Single-agent Ibrutinib for Rituximab-refractory Waldenstrom Macroglobulinemia: final analysis of the substudy of the phase III Innovate(TM) trial","volume":"27","author":"Trotman","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clml.2025.06.017_bib0086","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.06.017_bib0088","doi-asserted-by":"crossref","unstructured":"Castillo J, Sarosiek S, Branagan A, Keudell Gv, Ramirez-Gamero A, Treon S Clinical lymphoma, myeloma and leukemia. 2024;24:S203.","DOI":"10.1016\/S2152-2650(24)02192-X"},{"issue":"7","key":"10.1016\/j.clml.2025.06.017_bib0089","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood.2023022420","article-title":"Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naive Waldenstrom macroglobulinemia","volume":"143","author":"Castillo","year":"2024","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2025.06.017_bib0090","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.06.017_bib0092","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/bloodadvances.2023010906","article-title":"Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstrom macroglobulinemia","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2025.06.017_bib0093","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.seminhematol.2025.04.001","article-title":"Report of Consensus Panel 3 from the 12th International Workshop on Waldenstr\u00f6m\u2019s Macroglobulinemia on the management of patients with high-risk disease","volume":"62","author":"Kapoor","year":"2025","journal-title":"Sem Hematol"},{"issue":"4","key":"10.1016\/j.clml.2025.06.017_bib0094","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2018-10-879593","article-title":"Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study","volume":"133","author":"Castillo","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.06.017_bib0095","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/bjh.20016","article-title":"Zanubrutinib for the treatment of Bing-Neel syndrome","volume":"206","author":"Sarosiek","year":"2025","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2025.06.017_bib0096","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/s41375-025-02581-y","article-title":"Zanubrutinib in Bing Neel syndrome: efficacy and tolerability","volume":"39","author":"Becking","year":"2025","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2025.06.017_bib0097","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.seminhematol.2023.03.002","article-title":"Report of Consensus Panel 6 from the 11 th International Workshop on Waldenstrom's macroglobulinemia on management of Waldenstrom's macroglobulinemia related amyloidosis","volume":"60","author":"Merlini","year":"2023","journal-title":"Semin Hematol"},{"issue":"4","key":"10.1016\/j.clml.2025.06.017_bib0098","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.25023","article-title":"Ibrutinib discontinuation in Waldenstrom macroglobulinemia: etiologies, outcomes, and IgM rebound","volume":"93","author":"Gustine","year":"2018","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.clml.2025.06.017_bib0099","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.3324\/haematol.2017.186908","article-title":"Ibrutinib withdrawal symptoms in patients with Waldenstrom macroglobulinemia","volume":"103","author":"Castillo","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2025.06.017_bib0100","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2009.25.3237","article-title":"Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia","volume":"28","author":"Ghobrial","year":"2010","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.clml.2025.06.017_bib0103","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/blood-2017-01-761726","article-title":"Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia","volume":"129","author":"Xu","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.06.017_bib0105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41408-025-01271-3","article-title":"Outcomes of patients with relapsed\/refractory lymphoplasmacytic lymphoma\/waldenstrom macroglobulinemia treated with venetoclax: a multicenter retrospective analysis","volume":"15","author":"Sawalha","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.06.017_bib0107","series-title":"Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstrom\u2019s Macroglobulinemia (BRAWM)","author":"Berinstein","year":"2024"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.06.017_bib0108","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1182\/blood-2024-198297","article-title":"A Phase II study of Pirtobrutinib and Venetoclax in previously treated patients with Waldenstr\u00f6m macroglobulinemia: an interim analysis","volume":"144","author":"Castillo","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.06.017_bib0109","doi-asserted-by":"crossref","first-page":"TPS7090","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7090","article-title":"BGB-11417-203: an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenstr\u00f6m macroglobulinemia","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.06.017_bib0110","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood-2024-199212","article-title":"Preliminary efficacy and safety of the Bruton Tyrosine Kinase degrader BGB-16673 in patients with relapsed or refractory Waldenstr\u00f6m macroglobulinemia: results from the phase 1 CaDAnCe-101 study","volume":"144","author":"Seymour","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.06.017_bib0111","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.clml.2025.06.017_bib0112","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib plus Venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol"},{"issue":"23","key":"10.1016\/j.clml.2025.06.017_bib0113","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"34","key":"10.1016\/j.clml.2025.06.017_bib0114","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus Venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.06.017_bib116","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1111\/bjh.15909","article-title":"Importance of sequential analysis on TP53 variation in patients with Waldenstr\u00f6m macroglobulinemia","volume":"186","author":"Christian","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.06.017_bib117","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjh.15560","article-title":"TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstrom macroglobulinemia","volume":"184","author":"Gustine","year":"2019","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.clml.2025.06.017_bib118","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1158\/1078-0432.CCR-17-0007","article-title":"TP53 mutation and Its Prognostic Significance in Waldenstr\u00f6m Macroglobulinemia","volume":"23","author":"Poulain","year":"2017","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:53:59Z","timestamp":1768388039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2152265025002174"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | The Optimal Management of Waldenstr\u00f6m Macroglobulinemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}